Skip to product information
1 of 2

Pure Wellness Medical Supplements

PURE Wellness Liver Support

Regular price
$78.50 USD
Regular price
Sale price
$78.50 USD
  • Description
  • Serving Size: 3 capsules per day          240 capsules per bottle    80-day supply

    Directions: As a dietary supplement, take three (3) capsules with 8-12 fl oz of water daily.

    BENEFITS: An advanced formula made to support and enhance healthy liver function. Contains ingredients that have been used to treat liver disorders for over 2,000 years. Studies suggest that they may have a protective and regenerative effects on the liver and reduce liver enzymes.


    IMPORTANT FACTS:

    MILK THISTLE/SILYMARIN: Acts as an antioxidant by reducing free radical production, creating a detoxifying effect.

    ARTICHOKE LEAF EXTRACT: Helps remove toxins from the liver, while also promoting the growth of new tissue.

    ALPHA LIPOIC ACID: Powerful antioxidant that protects against Acetaminophen-induced liver damage.

    TUDCA: Improves overall liver function and drastically lowers inflammation.

    SCHISANDRA CHINENSIS: Produces a strong protective effect to prevent liver injury and inflammation. Helps to decrease AST & ALT levels, in addition to decreasing triglyceride levels.

    GLUTAMINE: Regulates liver metabolism and transport, important in ammonia detoxification, and preserves glutathione detoxification. Enhances liver antioxidant effect and has protective effect on the liver.

     

  • Clinical evidence
  • Evidence shows Milk Thistle (Silymarin) is often promoted for its liver-protecting effects and is regularly used as a complementary therapy by people who have liver damage (1,2,3). Studies have shown improvements in liver function in people with liver diseases who have taken a milk thistle supplement, suggesting it could help reduce liver inflammation and liver damage (4). A randomized control study by Hajagha et al. showed that silymarin decreased liver transaminase activities in non-alcoholic fatty liver disease (5). Studies have shown that Tauroursodeoxycholic Acid [TUDCA] improves liver function in patients with liver cirrhosis (6), hepatitis C virus [HCV]-related chronic hepatitis (7), and cholangitis (8). One study by Kim and colleagues showed how the endoplasmic reticulum which is responsible for producing secretory proteins of the cell and is abundant in liver tissues can decrease cellular stress and prevent cell death called apoptosis (9). Other studies have shown that TUDCA drastically lowers serum liver enzymes [ALT, AST, and ALP] that are markers of liver inflammation (9). Using Artichoke Leaf Extract the leaf of the C. scolymus has been used for centuries as an antimicrobial, anti-inflammatory, choleretic, hepatoprotective, cholesterol-lowering, lipid-lowering, and glucose-lowering substance in Turkey, Southern Europe and Mediterranean countries (10,11). Several in vivo and in vitro studies have been conducted to examine the applications of C. scolymus leaves. As a result of these studies -in addition to the traditional usage- anti-carcinogenic, anti-apoptotic and anti-HIV characteristics were also determined (12,13,14). The reason for the extensive usage of the leaf of the C. scolymus is described as being due to the additive and synergistic effects of the various compounds in the structure. There have been several studies associated with liver pathology and the C. scolymus leaf extract. Gebhardt (15) demonstrated the antioxidant and hepatoprotective effects of the C. scolymus leaf extract in primary cultured rat hepatocytes. Additionally, in a study with human leukocyte cultures, caffeic acid-, chlorogenic acid-, cynarin- and lutein-containing C. scolymus leaf extracts have been reported to have antioxidative effects, with the C. scolymus leaf extract expressing its antioxidant affects as a radical scavenger and a PMA-induced radical generation inhibitor (16). Furthermore, as a result of in vivo studies in rats, the C. scolymus leaf extract has been suggested to reduce lipid peroxidation (17) and protein oxidation as well as increase glutathione peroxidase activity (18). Studies done with Schisandra chinensis show it to have a strong protective effect against toxic damage to the liver (19). It has proven effective against liver damage in those suffering from liver disease (19). Yuan et al. showed Schisandra chinensis to have a significant protective effect on the liver injury induced by ethanol by reducing the oxidative stress (20). They demonstrated Schisandra chinensis acidic polysaccharide to significantly reduce serial AST and ALT levels in the injured liver and HepG2 cells induced by ethanol and also decrease triglyceride levels in the liver tissue (20). Glutamine plays an important role in ammonia detoxification in the liver and regulates liver metabolism and transport (21). A study performed by Hong and colleagues concluded that glutamine preserves hepatic glutathione, protects the liver, and improves survival during acetaminophen toxicity (22). They also noted that glutamine may augment host defenses by enhancing antioxidant protection (22). Alpha lipoic acid [ALA] an antioxidant that protects against acetaminophen-induced liver damage (23), high-fat diet induced-fatty liver (24), concanavalin A-induced hepatitis (25), lipopolysaccharide induced-acute liver injury (26), and liver cirrhosis (27). One study by Hosseinpour-Arjmand and colleagues demonstrated that ALA intake resulted in a significant improvement in fatter liver grade of the patients (28). Green tea extract has been shown to decrease inflammation caused by liver disease and show a significant reduction in liver enzyme levels (29). Pezeshki et al. showed a significant reduction in ALT and AST levels after 12 weeks intake of green tea extract (30). Hussain and colleagues showed that green tea extract patients showed a significant improvement in lipid profile, aminotransferases and inflammatory markers in addition to 67.5% regression of fatty liver changes on ultrasound (31). 

  • References
  • 1. Ludovico Abenavoli, Raffaele Capasso, Natasa Milic, Francesco Capasso
    Milk thistle in liver diseases: past, present, future Phytotherapy Research  2010 Oct;24(10):1423-32. doi: 10.1002/ptr.3207.  
    2. M R Losser, D Payen. Mechanisms of liver damage Semin Liver Dis. 1996 Nov;16(4):357-67.  doi: 10.1055/s-2007-1007249.  
    3. Alessandro Federico, Marcelloallio, Carmelina Loguercio. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years Molecules. 2017 Jan 24;22(2):191. doi: 10.3390/molecules22020191. 
    4. Navaneethakrishnan Polachi, Guirong Bai, Tingyang Li, Yang Chu, Xiangyang Wang, Shuming Li, Ning Gu, Jiang Wu, Wei Li, Yanjun Zhang, Shuiping Zhou, He Sun, Changxiao Liu. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review Eur J Med Chem. 2016 Nov 10;123:577-595. doi: 10.1016/j.ejmech.2016.07.070. Epub 2016 Jul 29.  
    5. Hajagha Mohammadi A.A., Ziaei Amir, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Hepatitis. Monthly summer 2008, Volume 8, Number 3; Page(s) 191 To 195.
    6. Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XH, J Huazhong. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. Univ Sci Technolog Med Sci. 2013 Apr;33(2):189-194. doi: 10.1007/s11596-013-1095-x
    7. Crosignani A, Budillon G, Cimino L, Del Vecchio Blanco C, Loguercio C, Ideo G, Raimondo G, Stabilini R, Podda M. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology. 1998 Sep-Oct;45(23):1624-9.
    8. Ma H, Zeng M, Han Y, Yan H, Tang H, Sheng J, Hu H, Cheng L, Xie Q, Zhu Y, Chen G, Gao Z, Xie W, Wang J, Wu S, Wang G, Miao X, Fu X, Duan L, Xu J, Wei L, Shi G, Chen C, Chen M, Ning Q, Yao C, Jia J. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016 Nov;95(47):e5391. doi: 10.1097/MD.0000000000005391
    9. Sou Hyun Kim, Doyoung Kwon, Seunghyun Lee, Sung Hwan Ki, Hye Gwang Jeong,Jin Tae Hong, Yun-Hee Lee, Young-Suk Jung. Polyhexamethyleneguanidine Phosphate-Induced Cytotoxicity in Liver Cells Is Alleviated by Tauroursodeoxycholic Acid (TUDCA) via a Reduction in Endoplasmic Reticulum Stress. Cells 2019, 8(9), 1023; https://doi.org/10.3390/cells8091023. Received: 5 July 2019 / Revised: 26 August 2019 / Accepted: 30 August 2019 / Published: 3 September 201
    10. Lattanzio V, Kroon PA, Linsalata V, Cardinali A. Globe artichoke: a functional food and source of nutraceutical ingredients. J Funct Foods. 2009;1(2):131–144. doi: 10.1016/j.jff.2009.01.002.
    11. Jimenez-Escrig A, Dragsted LO, Daneshvar B, Pulido R, Saura-Calixto F. In vitro antioxidant activities of edible artichoke (Cynara scolymus L.) and effect on biomarkers of antioxidants in rats. J Agric Food Chem. 2003;51(18):5540–5545. doi: 10.1021/jf030047e. 
    12. Miccadei S, Di Venere D, Cardinali A, Romano F, Durazzo A, Foddai MS, Fraioli R, Mobarhan S, Maiani G. Antioxidative and apoptotic properties of polyphenolic extracts from edible part of artichoke (Cynara scolymus L.) on cultured rat hepatocytes and on human hepatoma cells. Nutr Cancer. 2008;60(2):276–283. doi: 10.1080/01635580801891583.
    13. Robinson WE, Reinecke MG, Abdel-Malek S, Jia Q, Chow SA. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci USA. 1996;93(13):6326–6331. doi: 10.1073/pnas.93.13.6326.
    14. Yang SS, Cragg GM, Newman DJ, Bader JP. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J Nat Prod. 2001;64(2):265–277. doi: 10.1021/np0003995. 
    15. Gebhardt R. Antioxidative and protective properties of extracts from leaves of the artichoke (Cynara scolymus L.) against hydroperoxide-induced oxidative stress in cultured rat hepatocytes. Toxicol Appl Pharmacol. 1997;144(2):279–286. doi: 10.1006/taap.1997.8130. 
    16. Pérez-García F, Adzet T, Cañigueral S. Activity of artichoke leaf extract on reactive oxygen species in human leukocytes. Free Radic Res. 2000;33(5):661–665. doi: 10.1080/10715760000301171. 
    17. Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra M. Efficacy of different Cynara scolymus preparations on liver complaints. J Ethnopharmacol. 2003;86(2):203–211. doi: 10.1016/S0378-8741(03)00076-X. 
    18. Jimenez-Escrig A, Dragsted LO, Daneshvar B, Pulido R, Saura-Calixto F. In vitro antioxidant activities of edible artichoke (Cynara scolymus L.) and effect on biomarkers of antioxidants in rats. J Agric Food Chem. 2003;51(18):5540–5545. doi: 10.1021/jf030047e.
    19. Ni Cheng, Naiyan Ren, Hui Gao, Xingsheng Lei, Jianbin Zheng, Wei Cao. Antioxidant and hepatoprotective effects of Schisandra chinensis pollen extract on CCl4-induced acute liver damage in mice Food Chem Toxicol. 2013 May;55:234-40. doi: 10.1016/j.fct.2012.11.022. Epub 2012 Nov 28.  
    20. Rongshuang Yuan, Xue Tao, Shuang Liang, Yan Pan, He Li, Jinghui Sun, Wenbo Ju, Xiangyan Li, Jianguang Chen, Chunmei Wang. Protective effect of acidic polysaccharide from Schisandra chinensis on acute ethanol-induced liver injury through reducing CYP2E1-dependent oxidative stress. Biomedicine & Pharmacotherapy 99 (2018) 537-542

     


    21. Dieter Häussinger, Dirk Graf, Oliver H. Weiergräber. Glutamine and Cell Signaling in Liver.  The Journal of Nutrition, Volume 131, Issue 9, September 2001, Pages 2509S–2514S, https://doi.org/10.1093/jn/131.9.2509S
    22. Roy W. Hong, M.D., Jan D. Rounds, B.S., William S. Helton, M.D., Malcolm K. Robinson, M.D., Douglas W. Wilmore, M.D. Glutamine Preserves Liver Glutathione After Lethal Hepatic Injury. Ann. Surg. February 1992
    23. Mahmoud YI, Mahmoud AA, Nassar G. Alpha-lipoic acid treatment of acetaminophen-induced rat liver damage Biotech Histochem. 2015;90:594–600. doi: 10.3109/10520295.2015.1063005. 
    24. Yang Y, Li W, Liu Y, Sun Y, Li Y, Yao Q, Li J, Zhang Q, Gao Y, Gao L, Zhao J. Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway.  J Nutr Biochem. 2014;25:1207–1217. doi: 10.1016/j.jnutbio.2014.06.001. 
    25. Fei M, Xie Q, Zou Y, He R, Zhang Y, Wang J, Bo L, Li J, Deng X. Alpha-lipoic acid protects mice against concanavalin A-induced hepatitis by modulating cytokine secretion and reducing reactive oxygen species generation. Int Immunopharmacol. 2016;35:53–60. doi: 10.1016/j.intimp.2016.03.023. 
    26. Hahm JR, Noh HS, Ha JH, Roh GS, Kim DR. Alpha-lipoic acid attenuates adipocyte differentiation and lipid accumulation in 3T3-L1 cells via AMPK-dependent autophagy. Life Sci. 2014;100:125–132. doi: 10.1016/j.lfs.2014.02.001.
    27. Cao X, Chen A, Yang P, Song X, Liu Y, Li Z, Wang X, Wang L, Li Y. Alpha-lipoic acid protects cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy.  Biochem Biophys Res Commun. 2013;441:935–940. doi: 10.1016/j.bbrc.2013.10.166. 
    28. Sonya Hosseinpour-Arjmand MSc,Farshad Amirkhizi PhD,Mehrangiz Ebrahimi-Mameghani PhD. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Volume 44, Issue 2, April 2019: Pages 258-267
    29. Ali Pezeshki, Sara Safi, Awat Feizi, Gholamreza Askari, Fatemeh Karami. The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease Int J Prev Med. 2016 Feb 1;7:28.  doi: 10.4103/2008-7802.173051. eCollection 2016.  
    30. Ali Pezeshki, Sara Safi, Awat Feizi, Gholamreza Askari, Fatemeh Karami. The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease. Int J Prev Med. 2016; 7: 28. Published online 2016 Feb 1. doi: 10.4103/2008-7802.173051
    31. Mazhar Hussain, Habib-Ur-Rehman, Lubna Akhtar. Therapeutic benefits of green tea extract on various parameters in non-alcoholic fatty liver disease patients. Pak J Med Sci. 2017 Jul-Aug; 33(4): 931–936. doi: 10.12669/pjms.334.12571